Trial Profile
Pharmacokinetic study of gefitinib in patients with non-small cell lung cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 11 Dec 2017
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacokinetics
- 07 Dec 2017 Status changed from recruiting to active, no longer recruiting.
- 03 Sep 2015 New trial record